Everything tagged "growth" across the TickerSpark archives.
Thermo Fisher is delivering strong revenue, margin, and EPS growth across its core life sciences businesses, but the stock already prices in much of the recovery. The report lands on a Hold as valuation and leverage limit upside from here.
Moody's combines a high-margin ratings franchise with a fast-growing analytics platform, driving strong earnings and recurring revenue. Valuation remains the main constraint, but execution and issuance strength support a Buy case.
Sea Ltd is turning into a profitable, cash-generating consumer internet platform as Shopee, Monee and Garena all post strong growth. The stock looks attractive for moderate-risk investors, though execution and regulatory risk remain real.
Equifax is showing solid growth across Workforce Solutions, USIS, and International, with AI and cloud investments supporting the long-term thesis. But leverage, mortgage exposure, and a rich valuation keep the stock in Hold territory.
Super Micro Computer is riding explosive AI infrastructure demand, with fiscal 2026 revenue up 78% to $39.1B and a $65B-$72B fiscal 2027 guide. But heavy inventory, negative free cash flow, and internal-control concerns keep the stock at Hold.
Waste Connections posted solid Q2 growth, raised full-year guidance, and continues to benefit from pricing power and acquisition-led expansion. Valuation and leverage remain the main offsets to an otherwise durable cash-generating model.
Hasbro’s investment case is shifting toward Wizards of the Coast, Magic: The Gathering, and licensing, with strong Q3 growth and raised guidance. The main offset is a stretched balance sheet that keeps execution risk elevated.
Interactive Brokers combines rapid account growth, record profitability, and a fortress balance sheet, but the stock already trades at a premium multiple. The report still supports a Buy for investors who can tolerate trading and rate volatility.
Monster Beverage posted 20.2% Q2 sales growth and 19.0% EPS growth, powered by international expansion and a strong energy-drink franchise. The stock remains a Hold as execution is strong but valuation is still demanding.
Molina Healthcare faces a sharp 2026 earnings reset, but Medicaid rate normalization and improving Medicare duals could support a 2027 rebound. The stock looks more like a Hold than a Buy while execution risk remains high.
EQT’s Buy case is built on Appalachian scale, improving execution, and growing demand-linked contracts. The report highlights stronger production guidance, lower capex, and a repaired balance sheet, offset by commodity-price sensitivity.
Neptune is scaling quickly in underpenetrated flood insurance, with 32.8% revenue growth and strong underwriting economics. But the stock’s premium valuation and leverage keep the rating at Hold.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime